Last checked at 9 Mar 2021 07:00
This is an Reach announcement and the information contained is not considered to be material or to have a significant impact on management's expectations of the Company's performance. Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on Reach.
9 March 2021
Directa Plus plc
("Directa Plus" or the "Company")
Successful Absorption Evaluation Test
Study finds zero absorption of G+® graphene, underlining safety for textile applications
Directa Plus (AIM: DCTA), a leading producer and supplier of graphene nanoplatelets based products for use in consumer and industrial markets, is pleased to announce that it has received another positive test result relating to the potential for absorption of the Company's pristine graphene nanoplatelets powder (Pure G+®) through human skin. This latest in vitro test showed that there is no absorption potential for Pure G+®, taking the total number of positive in vitro test results to eight.
The study was carried out by an independent third party and followed the standards of OECD 428 ("In vitro evaluation of the absorption potential of a product throughout reconstructed human epidermis"). The purpose of the test was the evaluation of the skin absorption potential of Pure G+® through an in vitro reconstructed human epidermis. Pure G+ was applied on the tissue surface for six and 24 hours and at the end of the experimental time, a calculation of the quantity of Pure G+® graphene that had penetrated through the epidermis was performed.
The acquisition of further successful results from in vitro tests of the Company's hypoallergenic, non-toxic products is vital for their use in textile markets where customers have to be certain of the safety of the apparel they produce and market.
Directa Plus has continued to launch its own branded clothing collections with the latest available at:
https://graphene-plus.com/cosmic-collection/
Giulio Cesareo, Chief Executive of Directa Plus, commented: "Our suite of successful in vitro tests proves to customers in the textile industry that they can safely adopt our products to create exciting new garments enhanced by our graphene products. We will continue to ensure that our products are tested to the highest possible standards before releasing them to our target markets, in keeping with our core values."
For further information please visit http://www.directa-plus.com/ or contact:
Directa Plus plc | +39 02 36714458 |
Giulio Cesareo, CEO |
|
Marco Ferrari, CFO |
|
Cenkos Securities plc (Nominated Adviser and Joint Broker) | +44 131 220 6939 |
Neil McDonald / Pete Lynch |
|
N+1 Singer (Joint Broker) | +44 20 7496 3069 |
Rick Thompson / Phil Davies |
|
Tavistock (Financial PR and IR) | +44 20 7920 3150 |
Simon Hudson / Edward Lee |
|
About Directa Plus
Our focus is principally on the two sectors in which we have strong commercial advantage through developed and launched products and a technological lead: environmental (based on our Grafysorber® product) and textiles (based on our G+ products). In addition, we will continue to pursue opportunities in elastomers and composites (including tyres and asphalt), also using our G+ products. All our products are hypoallergenic, non-toxic and sustainably produced.
-ends-